We found trametinib, a selective MEK inhibitor FDA-approved for BRAF mutant cancers (18, 40), greatly enhanced the localization of desmosomal proteins to cell-cell junctions in NHEKs despite treatment with dabrafenib or vemurafenib (Figure 2, B–D). The gene discussed is BRAF; the disease is cancer.